Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

Latest News

Australian PM: WTO needs mending to keep up with the times

Jun 17, 2019

SINGAPORE — Australian Prime Minister Scott Morrison said Friday that the World Trade Organization needs mending to keep up with the times. Morrison said many leaders attending the Group of 20 summit in Osaka later this month share the view. "There is a strong consensus about the need to modernize the WTO and its rules," he said. "We need to mend it, we don't need to break it, and mending it requires a lot of partnership," he added. "Just now it's the technical practical things that need to get done." Morrison, who spoke at a lunch organized by the Australian...

Asian stocks mixed after Trump threatens Mexico tariffs

Jun 17, 2019

SINGAPORE — Asian stocks were mixed on Thursday as traders kept a close watch on impending U.S. tariffs on Mexico while trade talks with Beijing remained at a standstill. Japan's Nikkei 225 index added 0.3% to 20,832.46 while the Shanghai Composite index lost 0.5% to 2,848.34. The benchmark in Shenzhen, a smaller, more domestic-oriented market, tumbled 1.5% to 1,471.73. Hong Kong's Hang Seng added 0.3% to 26,965.76 and Australia's S&P ASX 200 advanced 0.5% to 6,392.20. Shares fell in Taiwan and Singapore but rose in the Philippines. South Korean markets were closed for a holiday. American and Mexican officials said...

China vows military action if Taiwan, sea claims opposed

Jun 17, 2019

SINGAPORE — China's defense minister warned Sunday that its military will "resolutely take action" to defend Beijing's claims over self-ruled Taiwan and disputed South China Sea waters. Speaking at an annual security conference in Singapore, Gen. Wei Fenghe did not direct the threat at the U.S. but loaded his address with criticism of activities by Washington, including support for Taiwan and leading so-called "freedom of navigation" operations in the strategic waterways that China virtually claims as its own. Wei said the People's Liberation Army would not "yield a single inch of the country's sacred land." China's ruling Communist Party maintains...

S&P upgrades Indonesia credit after Widodo election win

Jun 17, 2019

JAKARTA, Indonesia — Ratings agency Standard & Poor's said Friday it has upgraded Indonesia's sovereign credit rating following the election of Joko Widodo to a second term as president. The organization said the upgrade reflects Indonesia's strong economic growth prospects, which "we expect to remain following the reelection of Joko Widodo recently." The long-term rating was increased to BBB from BBB minus and potentially makes it easier for the government to borrow abroad and at lower interest rates. Official results last week confirmed Widodo won 55.5% of the vote in the April 17 election. His opponent Prabowo Subianto has alleged...

Challenge to Indonesia vote makes big claims, weak on proof

Jun 17, 2019

JAKARTA, Indonesia — The court challenge to Indonesia's presidential election from the losing candidate claims that the police, intelligence agency and other state institutions were biased in favor of the incumbent, but its evidence for "massive" fraud is mainly printouts of news articles. Former General Prabowo Subianto has refused to accept the results of the April 17 election and instead declared himself the winner. Seven people died in what police say was orchestrated rioting in the capital last week after official election results confirmed President Joko Widodo had won a second term with 55.5% of the vote. Subianto's legal challenge...